Published in AAPS J on November 19, 2009
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol (2010) 1.66
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem (2012) 1.46
Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging. PLoS One (2011) 1.35
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res (2014) 1.09
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2013) 0.98
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 0.92
Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun (2015) 0.90
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis (2015) 0.86
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J (2010) 0.84
The development of potential antibody-based therapies for myeloma. Blood Rev (2014) 0.81
Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis (2015) 0.81
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs (2015) 0.81
Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom (2015) 0.80
Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. MAbs (2013) 0.79
Monoclonal antibody therapy for Junin virus infection. Proc Natl Acad Sci U S A (2016) 0.79
Therapeutic aptamers: developmental potential as anticancer drugs. BMB Rep (2015) 0.79
Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J (2012) 0.79
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. J Biol Chem (2015) 0.79
Pharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice. Prostate Cancer (2014) 0.78
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs (2015) 0.78
Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies. AAPS J (2014) 0.77
Misdiagnosis of late-onset Lyme arthritis by inappropriate use of Borrelia burgdorferi immunoblot testing with synovial fluid. Clin Vaccine Immunol (2012) 0.77
Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. AAPS J (2015) 0.76
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol (2015) 0.75
Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. Int J Pharm (2013) 0.75
Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. Drug Metab Dispos (2015) 0.75
Raman spectroscopy characterization of antibody phases in serum. MAbs (2014) 0.75
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb. EJNMMI Res (2013) 0.75
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies. PLoS One (2015) 0.75
Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn (2015) 0.75
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharm Res (2017) 0.75
Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods (2017) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
IgG Fc receptors. Annu Rev Immunol (2001) 8.63
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev (2005) 7.56
High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer (2004) 5.99
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Characterization of a human B lymphocyte-specific antigen. J Immunol (1980) 5.76
Transport of molecules in the tumor interstitium: a review. Cancer Res (1987) 5.74
Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res (1989) 5.62
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis (2004) 5.49
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res (2000) 4.89
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
Th17 cells in human disease. Immunol Rev (2008) 4.27
The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet (1966) 3.99
Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer (2002) 3.96
Transport of molecules across tumor vasculature. Cancer Metastasis Rev (1987) 3.67
Barriers to drug delivery in solid tumors. Sci Am (1994) 3.57
Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol (1999) 3.42
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med (1999) 3.34
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev (1990) 2.75
Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood (2002) 2.65
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (1990) 2.61
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Significance of blood vessel leakiness in cancer. Cancer Res (2002) 2.43
Omalizumab for asthma. N Engl J Med (2006) 2.31
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood (2002) 2.28
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis (1998) 2.24
Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today (2006) 2.21
Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum (2006) 2.17
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol (1997) 1.98
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays (1991) 1.93
Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol (2004) 1.91
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res (2003) 1.87
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol (2006) 1.85
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn (2007) 1.82
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 1.80
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Drug targeting to the brain. Pharm Res (2007) 1.79
Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem (2002) 1.73
Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med (2007) 1.69
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis (2007) 1.66
Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther (1994) 1.64
Biology of angiogenesis and invasion in glioma. Neurotherapeutics (2009) 1.61
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol (2001) 1.58
Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology (2007) 1.53
Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol (2001) 1.52
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol (2008) 1.42
Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol (2002) 1.41
Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res (1990) 1.39
Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry (1995) 1.39
Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem (2007) 1.36
FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today (1997) 1.30
The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation (1997) 1.25
Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol (1981) 1.23
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today (2007) 1.22
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol (2001) 1.22
The pharmacological basis of anti-IgE therapy. Nat Biotechnol (2000) 1.20
Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm (2009) 1.16
Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol (2008) 1.15
Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol (1983) 1.14
Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer (2002) 1.11
Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol (2002) 1.11
Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev (2000) 1.11
Extravascular transport in normal and tumor tissues. Crit Rev Oncol Hematol (1986) 1.10
Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol (2005) 1.09
Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood (2001) 1.09
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J (2008) 1.09
Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage (2000) 1.09
Clinical relevance of Fc gamma receptor polymorphisms. Ann N Y Acad Sci (1997) 1.07
In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res (1990) 1.06
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) (2000) 1.00
Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A (2003) 1.00
Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol (2009) 0.94
Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer (1998) 0.93
Disproportionate elevation of the immunoglobulin G1 concentration in cerebrospinal fluids of patients with multiple sclerosis. Infect Immun (1979) 0.93
Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol (2004) 0.93
The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol (1992) 0.92
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol (2007) 0.92
Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol (2003) 0.88
Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol (2006) 0.86
IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien Klin Wochenschr (2001) 0.86
Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med (2001) 0.85
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs (2009) 0.84
Next-generation protein drugs. Nat Biotechnol (2004) 0.82
Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today (2009) 0.81
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J (2010) 0.84
Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today (2009) 0.81
Monoclonal antibody lead characterization: in vitro and in vivo methods. Methods Mol Biol (2012) 0.75